ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	PEARSON Andrew D. J. SCOBIE Nicole NORGA Koenraad LIGAS Franca CHIODIN Davy BURKE Amos MINARD-COLIN Veronique ADAMSON Peter MARSHALL Lynley V. BALAKUMARAN Arun BENETTAIB Bouchra BHARGAVA Pankaj BOLLARD Catherine M. BOLOTIN Ellen BOMKEN Simon BUECHNER Jochen BURKHARDT Birgit CARON Hubert COPLAND Christopher DEMOLIS Pierre EGOROV Anton FARHAN Mahdi ZUGMAIER Gerhard GROSS Thomas HORTON-TAYLOR Danielle KLAPPER Wolfram LESA Giovanni MARCUS Robert MILES Rodney R. NOTTAGE Kerri PACAUD Lida RICAFORT Rosanna SCHRAPPE Martin ŠTĚRBA Jaroslav VEZAN Remus WEINER Susan KIM Su Young REAMAN Gregory VASSAL Gilles
Rok publikování	2019
Druh	Článek v odborném periodiku
Časopis / Zdroj	European Journal of Cancer
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	http://dx.doi.org/10.1016/j.ejca.2019.01.013
Doi	http://dx.doi.org/10.1016/j.ejca.2019.01.013
Klíčová slova	Paediatric oncology; Mature B-cell malignancies; Medicinal product development
Popis	Paediatric Strategy Forums have been created by the multistakeholder organisation, ACCELERATE, and the European Medicines Agency to facilitate dialogue between all relevant stakeholders and suggest strategies in critical areas of paediatric oncology drug development. As there are many medicines being developed for B-cell malignancies in adults but comparatively few in children with these malignancies, a Paediatric Strategy Forum was held to discuss the best approach to develop these products for children. It was concluded that as current frontline therapy is highly successful, despite associated acute toxicity, de-escalation of this or substitution of presently used drugs with new medicines can only be undertaken when there is an effective salvage regimen, which is currently not available. Therefore priority should be given to developing treatment for patients with relapsed and refractory mature B-cell lymphomas. The consensus of the clinicians attending the meeting was that CAR T-cells, T-cell engagers and antibody drug conjugates (excluding those with a vinca alkaloidelike drug) presently have the greatest probability of providing benefit in relapse in view of their mechanism of action. However, as producing autologous CAR T-cells currently takes at least 4 weeks, they are not products which could be quickly employed initially at relapse in rapidly progressing mature B-cell malignancies but only for the consolidation phase of the treatment. Global, industry-supported, academic-sponsored studies testing compounds from different pharmaceutical companies simultaneously should be considered in rare populations, and it was proposed that an international working group be formed to develop an overarching clinical trials strategy for these disease groups. Future Forums are planned for other relevant paediatric oncologic diseases with a high unmet medical need and relevant molecular targets. (C) 2019 Elsevier Ltd. All rights reserved.
Související projekty:	CZECRIN - Český národní uzel Evropské sítě infrastruktur klinického výzkumu Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medecine" a "N-of-1 clinical trials"